A study showed that the expression rates of CPT1A and CPT1B were 50 times lower than normal in long-term bone marrow cultures (TBMC) of CML patients [88]. This evidence concerns the gene CPT1A and chronic myelogenous leukemia, BCR-ABL1 positive.